New Pfizer Pipeline Shows Progress And Growth In Vaccines, Biologics And High-Priority Disease Areas |
| Thursday, 28 January 2010 |
|
|
Friday, February 5, 2010
New Pfizer Pipeline Shows Progress And Growth In Vaccines, Biologics And High-Priority Disease Areas
Pfizer Inc. has provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development. 
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment